At ARVO 2025, in Salt Lake City, Utah, Danielle Gauthuer talked about her poster on autosomal dominant Alzheimer's disease in relation to optic nerve head drusen.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its ...

At ARVO 2025, in Salt Lake City, Utah, Roger Goldberg, MD, MBA, talked about his presentation on the effect of AREDS vitamins in geographic atrophy.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A recent study reveals a significant rise in childhood astigmatism linked to the COVID-19 pandemic, independent of myopia.

At ARVO 2025, in Salt Lake City, Utah, Viha Vig, talked about her poster presentation investigating the relationship between ocular and systemic mitochondrial diseases and dementia ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal ...

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and ...

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macu ...

Shifting from a regulatory role to driving innovation directly, Eydelman discusses how the Collaborative Community on ...